New hope for tough lung cancer: experimental drug IBI115 enters human testing
NCT ID NCT07559019
First seen May 11, 2026 · Last updated Jun 11, 2026 · Updated 8 times
Summary
This early-phase study tests a new drug called IBI115, alone or with other treatments, in 150 adults with advanced small cell lung cancer. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have measurable cancer and be between 18 and 75 years old.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the second affiliated hospital of AMU
RECRUITINGChongqing, Chongqing Municipality, 400037, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.